Randomized Phase II of TARCEVA (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme

Trial Profile

Randomized Phase II of TARCEVA (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Erlotinib (Primary) ; Carmustine; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2009 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2009 Primary endpoint 'Progression free survival rate' has not been met.
    • 23 Sep 2007 Results were presented at ECCO 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top